Abstract
The purpose of this study was to determine the comparison of the financial performance of state-owned pharmaceutical companies with private-owned pharmaceutical companies and find out what factors affect differences in company performance based on analysis of profitability, market value rations and EVA. This study using a quantitative approach using a comparative descriptive method that took a sample of 4 pharmaceutical companies listed on the Stock Excahange. The data analysis technique uses a different independent sample T-test by comparing financial data from state-owned and private pharmaceutical companies in the 2016-2018 period. The results of the study show that return on equity (ROE) analysis of state-owned pharmaceutical companies is not safe because there are significant differences in the precentage above 15% and private pharmaceutical above 15%. The earning per share (EPS) analysis results of state-owned companies reached 0,35 and private pharmaceutical companies reached 50,71. As well as economic value added (EVA) analysis produces data there are differences in financial performace where the state-owned pharmaceutical companies have increased and privat pharmaceutical companies have decreased.
Highlights
Pendahuluan Globalisasi perekonomian akan membuka peluang pasar baru terhadap produk dalam negeri namun globalisasi perekonomian ini akan berdampak dikegiatan ekonomi serta perdagangan dibeberapa negara dan keberadannya menjadi dilema, peluang pasar mampu membuka produk-produk dalam negeri berupa pasar internasional dan disisi lain juga membuka peluang produkproduk luar negeri seperti pasar domestik
The purpose of this study was to determine the comparison of the financial performance of state-owned pharmaceutical companies
out what factors affect differences in company performance based on analysis of profitability
Summary
Berdasarkan tabel output 2 “Group Statistics” diatas menjelaskan bahwa perusahaan farmasi BUMN memperoleh nilai mean 16,3700. Pada perusahaan farmasi BUMN yang berdasarkan standar deviasi dan standar error mean lebih tinggi daripada perusahaan farmasi milik swasta. Jadi disimpulan bahwa terdapat perbedaan pada kinerja keuangan perusahaan farmasi milik BUMN dengan perusahaan farmasi milik swasta
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
